Page 3 - Factor Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Author Bio George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies. Follow @BudwellGeorge What happened Brooklyn ImmunoTherapeutics (NYSEMKT:BTX), a relative newcomer to the world of publicly traded biotech stocks, saw its shares rip higher in April by a stunning 1,230%, according to data provided by S&P Global Market Intelligence. The stock took flight last month for two related reasons: In late April, Broo...

Why Brooklyn ImmunoTherapeutics Is Surging Higher Again Today Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) is moving higher again on Monday morning as the stock continues to increase in popularity on the subreddit r/wallstreetbets. What Happened: The stock has soared over the last week after Reddit traders identified the stock as a low float high short interest short squeeze candidate. Last Thursday, the company announced it had acquired an exclusive license for mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited. “As a result ...

Share: Brooklyn Immuno Therapeutics Inc. (NYSE: BTX) shares are soaring Friday. The stock is likely continuing its run after the company paid $1 million towards the acquisition of a license for Factor Bioscience’s and Novellus mRNA gene editing and cell therapies technology. If the license agreement is completed, it allows Brooklyn Therapeutics to utilize a patented process to seek to develop gene-edited compounds using mRNA. Below is a chart analysis on the 15-minute timeframe. Brooklyn Therapeutics 15-Minute Chart Analysis The stock looks to have broken out of what technical traders may ...

Posted on 3044 Brooklyn ImmoTherapeutics LLC (NYSE: BTX)reported that is has acquired an exclusive license for mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited.  This will include an extensive patented process to develop gene editing compounds by utilizing mRNA which preclinical data has demonstrated a high level of efficiency.  mRNA cell reprogramming is considered the highest efficiency and footprint free technology that may be applied to allogeneic and autologous ce...

Novavax, Inc Novavax, Inc. is a clinical-stage vaccine company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. With the onset of the global pandemic last year, the company has also ventured into making COVID-19 vaccines. Despite not having any product in the market yet and facing delays in production, it is still expected to be one of the leading vaccine candidates. The company’s vaccine has proven to be just as potent as other vaccine frontrunners. On Tuesday, President Joe Biden hinted that Novavax’s vaccine may be ne...